Ixazomib did not have an adverse impact on quality of life in newly diagnosed multiple myeloma

Best Practice Nordic | Jun 2019 | EHA 2019 |

TOURMALINE-MM3 is a phase 3, double-blind, placebo-controlled study, where ixazomibimproved PFS, and is the first study to evaluate the impact ofmaintenance therapyon quality of life in postautologous stem cell transplant in newly diagnosed multiple myeloma. In this MEDtalk Fredrik Schjesvold present the data from the study showing, that active treatment with ixazomibdid not have an adverse impact on HRQoL.